Publication: Interleukin 6 in systemic sclerosis and potential implications for targeted therapy
Issued Date
2012-06-01
Resource Type
ISSN
14992752
0315162X
0315162X
Other identifier(s)
2-s2.0-84861805021
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Rheumatology. Vol.39, No.6 (2012), 1120-1124
Suggested Citation
Chayawee Muangchan, Janet E. Pope Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. Journal of Rheumatology. Vol.39, No.6 (2012), 1120-1124. doi:10.3899/jrheum.111423 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/14311
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Interleukin 6 in systemic sclerosis and potential implications for targeted therapy
Author(s)
Other Contributor(s)
Abstract
Objective. The purpose of this study was to review the potential importance of interleukin 6 (IL-6) in systemic sclerosis (SSc). Methods. PubMed and Scopus databases and American College of Rheumatology (from 2009-10) and European League Against Rheumatism abstracts (2009-11) were searched using keywords "scleroderma; SSc; cytokines; interleukins; interleukin 6" and publications were excluded if not pertaining to IL-6 in SSc. Data were extracted from selected articles to construct a cell interaction model of the effects of IL-6 in SSc. Results. A total of 416 reports were found (PubMed, n = 82; Scopus, n = 331; 3 abstracts); 372 were excluded (irrelevant) leaving 41 publications and 3 abstracts (39 from PubMed, 18 from Scopus; but 16 were repeated from PubMed search), where 40 suggested IL-6 was important in SSc and 4 did not. Effects of IL-6 in SSc were summarized schematically. Conclusion. Of the 44 publications, 40 suggested that IL-6 may be important in SSc, allowing for a conceptual framework within SSc including effects on macrophages, fibroblasts, plasma cells, monocytes, and extracellular matrix. The Journal of Rheumatology Copyright © 2012. All rights reserved.